Chardan Capital Reiterates Buy Rating on ProMIS Neurosciences, Inc. (PMN)

Market Context

ProMIS Neurosciences, Inc. operates in the Healthcare sector. The stock currently trades at $14.52 with a market capitalization of $11.3M. The stock has declined 48.3% over the past 52 weeks.

Analyst coverage from Chardan Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for ProMIS Neurosciences, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for ProMIS Neurosciences, Inc.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 28, 2026	Chardan Capital	Buy	N/A
Jul 27, 2026	Chardan Capital	Buy	N/A
Jul 08, 2026	Roth Capital	Buy	N/A
Jun 30, 2026	Cantor Fitzgerald	Overweight	N/A
Jun 24, 2026	HC Wainwright & Co.	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View PMN Stock Page